TapewireFind a company

person · Reporting owner

Ence Chuck

Disclosed activity across 2 companies

Tapewire entity
71409
SEC CIK
0001697779

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
NewAge, Inc.NBEV · Entity 129046Chief Financial OfficerSeptember 15, 2016February 14, 2017
RELMADA THERAPEUTICS, INC.RLMD · Entity 5498CA and CODecember 12, 2025December 16, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NewAge, Inc.

Report date September 15, 2016 · Filed February 14, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect422,702 Reported balance Holding disclosure · report date 2016-09-15 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 422,702

RELMADA THERAPEUTICS, INC.

Report date December 12, 2025 · Filed December 16, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12Direct828,000 Reported balance After 2025-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-12-12 · Grant · Acquired 828,000 · Balance 828,000

F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 12, 2025 Filed Dec 16, 2025 14:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Appreciation Rights · Derivative 828,000 $0.00 Strike: $4.06 $0.00
Disclosure

SEC source: 0001213900-25-121972 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 828,000

Underlying: Common Stock · 828,000 shares

Expires 2035-12-12

F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 12:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 136,000 $2.20 $299,200.00
Disclosure

SEC source: 0001213900-25-106838 · ownership.xml · nonDerivative · entry 1

Ence Chuck · CIK 0001697779 · CAO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 403,931

Read SEC document
June 26, 2025 Filed Jun 30, 2025 23:29 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 400,000 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001213900-25-059870 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2035-06-26

F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025.

Read SEC document
May 16, 2025 Filed May 20, 2025 22:02 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 228,961 $0.45 $103,330.10
Disclosure

SEC source: 0001213900-25-046086 · ownership.xml · nonDerivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,931

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $0.401 to $0.4892 per share, inclusive.

Read SEC document
May 24, 2024 Filed May 30, 2024 01:23 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 OtherStock Option (right to buy) · Derivative 54,624 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047633 · ownership.xml · derivative · entry 2

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,090

Underlying: Common Stock · 54,624 shares

Expires 2033-12-15

F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.

Read SEC document
May 24, 2024 Filed May 30, 2024 01:23 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 54,624 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047633 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,714

Underlying: Common Stock · 54,624 shares

Expires 2033-12-15

F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares.

Read SEC document
January 31, 2024 Filed Jan 31, 2024 23:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 13,670 $4.05 $55,429.12
Disclosure

SEC source: 0001213900-24-008557 · ownership.xml · nonDerivative · entry 3

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,970

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F4 · price: Purchase prices range from $3.93 to $4.17 per share, inclusive.

Read SEC document
January 30, 2024 Filed Jan 31, 2024 23:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 14,500 $3.87 $56,052.65
Disclosure

SEC source: 0001213900-24-008557 · ownership.xml · nonDerivative · entry 2

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,300

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F3 · price: Purchase prices range from $3.755 to $3.99 per share, inclusive.

Read SEC document
January 29, 2024 Filed Jan 31, 2024 23:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 10,800 $3.65 $39,438.36
Disclosure

SEC source: 0001213900-24-008557 · ownership.xml · nonDerivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,800

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $3.585 to $3.73 per share, inclusive.

Read SEC document
December 15, 2023 Filed Dec 19, 2023 22:27 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 82,090 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-23-097026 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · Chief Accounting and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,090

Underlying: Common Stock · 82,090 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on March 15, 2024.

Read SEC document
May 25, 2023 Filed May 30, 2023 21:06 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 321,238 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-23-044081 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 518,361

Underlying: Common Stock · 321,238 shares

Expires 2032-12-16

F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: 18,361 of the options immediately vested; 500,000 options vest in 16 equal quarterly installments commencing on March 16, 2023.

F2 · balance_after: 18,361 of the options immediately vested; 500,000 options vest in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
December 16, 2022 Filed Dec 21, 2022 00:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 OtherStock Option (right to buy) · Derivative 200,000 Not disclosed Strike: $19.03 Not disclosed
Disclosure

SEC source: 0001213900-22-081518 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 200,000 shares

Expires 2031-12-17

F1 · kind: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated.

F1 · shares: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated.

F2 · price: Not applicable.

F2 · derivative.exercise_date: Not applicable.

F3 · derivative.expiration_date: Original expiration date.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 22:31 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 197,123 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-22-081474 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and CO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,123

Underlying: Common Stock · 196,123 shares

Expires 2032-12-16

F1 · derivative.exercise_date: 18,361 of the shares are immediately vested; 178,762 shares vest in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
May 25, 2022 Filed May 26, 2022 22:39 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-22-029833 · ownership.xml · derivative · entry 2

Ence Chuck · CIK 0001697779 · CA and Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-12-17

F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol.

Read SEC document
May 25, 2022 Filed May 26, 2022 22:39 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 295,404 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-22-029833 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CA and Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 522,236

Underlying: Common Stock · 295,404 shares

Expires 2031-12-17

F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.

Read SEC document
December 17, 2021 Filed Dec 22, 2021 02:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 226,832 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-21-066820 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CAO and Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,832

Underlying: Common Stock · 226,832 shares

Expires 2031-12-17

F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022.

Read SEC document
January 07, 2021 Filed Jan 11, 2021 21:06 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantOptions to purchase common stock · Derivative 112,500 $0.00 Strike: $33.43 $0.00
Disclosure

SEC source: 0001213900-21-001416 · ownership.xml · derivative · entry 2

Ence Chuck · CIK 0001697779 · Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2031-01-07

F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period.

F2 · derivative.exercise_date: The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021.

Read SEC document
January 07, 2021 Filed Jan 11, 2021 21:06 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantOptions to purchase common stock · Derivative 112,500 $0.00 Strike: $33.43 $0.00
Disclosure

SEC source: 0001213900-21-001416 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2031-01-07

F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period.

Read SEC document
December 19, 2019 Filed Dec 23, 2019 22:00 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantOptions to purchase common stock · Derivative 60,000 $43.47 Strike: $43.47 $2,608,200.00
Disclosure

SEC source: 0001213900-19-026862 · ownership.xml · derivative · entry 1

Ence Chuck · CIK 0001697779 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-12-19

F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.